Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700246 | 0.85 | RORC (0.42) | RORCKDM1AGPR119KDM4EPKM | |
| SCHEMBL17294857 | 0.82 | DRD2 (0.40) | MEN1KMT2A | |
| SCHEMBL30742997 | 0.78 | NR1H2 (0.38) | MEN1KMT2AKDM1ATSHR | |
| SCHEMBL351086 | 0.77 | TSHR (0.52) | RORCOPRD1OPRK1GPR119ALOX15 | |
| SCHEMBL13771539 | 0.77 | TSHR (0.52) | RORCOPRD1OPRK1GPR119ALOX15 | |
| SCHEMBL17294854 | 0.77 | RORC (0.42) | RORCKDM1AABCB1GPR119ALOX15 | |
| SCHEMBL20584659 | 0.77 | RORC (0.42) | RORCKDM1AABCB1GPR119ALOX15 | |
| SCHEMBL12166405 | 0.77 | RORC (0.42) | RORCKDM1AABCB1GPR119ALOX15 | |
| SCHEMBL17294853 | 0.77 | RORC (0.42) | RORCKDM1AABCB1GPR119ALOX15 | |
| SCHEMBL20446551 | 0.77 | RORC (0.42) | RORCKDM1AABCB1GPR119ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149002-B1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9663530-B2 | 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663530-B2 | 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3149002-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2015181061-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066775-A1 | 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES | GRIN2C, NR3C2, HTR2C | RORC 231/4885MEN1 2735/4885KMT2A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.